SignalXSignalX

ENTA ENANTA PHARMACEUTICALS INC

8-K Current Report
Filed: March 12, 2026
Health Care
Pharmaceutical Preparations
ENANTA PHARMACEUTICALS INC Overview

ENANTA PHARMACEUTICALS INC (ENTA) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 5.07: Submission of Matters to a Vote of Security Holders

AI Filing Analysis
8-K

Item 5.07 · Submission of Matters to a Vote of Security Holders

  • • Directors re-elected: Bruce Carter (Ph.D.) with 81.4% support; Jay Luly (Ph.D.) with 99.2% support — notably high vote against Carter
  • • Equity plan amended to add 1,600,000 shares to 2019 Equity Incentive Plan, approved 78% For vs 21.6% Against — moderate shareholder resistance signals dilution concern
+2 more insights

Get deeper insights on ENANTA PHARMACEUTICALS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.